Core Insights - Smith+Nephew has signed an exclusive US distribution agreement with RMR Ortho to incorporate the A'TOMIC™ Nitinol Fixation System into its Trauma, Foot & Ankle, and Hand & Wrist portfolio, aimed at enhancing implant integrity and patient comfort [1][4] Group 1: Partnership and Product Details - The partnership with RMR Ortho enhances Smith+Nephew's fixation portfolio by adding a dynamic compression fixation solution that complements existing technologies [4] - The A'TOMIC Nitinol Fixation System utilizes proprietary manufacturing methods and unique nitinol properties to provide compressive fixation implants designed for stability in fusion, fracture, and osteotomy sites [4] - This collaboration is expected to deepen surgeon engagement and expand participation in high-frequency fracture and arthrodesis procedures [4][5] Group 2: Company Overview - Smith+Nephew is a global medical technology company focused on the repair, regeneration, and replacement of soft and hard tissue, with a mission to restore people's bodies and self-belief [8] - The company operates in over 100 countries and reported annual sales of $5.8 billion in 2024, positioning itself as a constituent of the FTSE100 [9]

Profitability improved as the company delivered its first full year of positive Adjusted EBITDA. Gross margin was 79% in the fourth quarter and 79.6% for the full year, with Maheshwari noting the full-year gross margin came in about 200 basis points above the company’s original 2025 guidance. He attributed the outperformance to stable average selling prices from favorable procedure mix and to operational initiatives such as supply chain efficiency and cost optimization.For the full year 2025, worldwide reve ...

SI-BONE (NasdaqGM:SIBN) Q4 2025 Earnings call February 23, 2026 04:30 PM ET Company ParticipantsAnshul Maheshwari - CFO and COOCaitlin Roberts - Director of MedTech Equity ResearchDavid Saxon - Managing DirectorLaura Francis - CEOMathew Blackman - Managing DirectorPatrick Wood - Managing DirectorSaqib Iqbal - VP of FP&A and Investor RelationsTravis Steed - Managing DirectorConference Call ParticipantsNone - AnalystNone - AnalystOperatorGood afternoon, and welcome to SI-BONE's fourth quarter 2025 earnings co ...

SI-BONE (NasdaqGM:SIBN) Q4 2025 Earnings call February 23, 2026 04:30 PM ET Company ParticipantsAnshul Maheshwari - CFO and COOCaitlin Roberts - Director of MedTech Equity ResearchDavid Saxon - Managing DirectorLaura Francis - CEOMathew Blackman - Managing DirectorPatrick Wood - Managing DirectorSaqib Iqbal - VP of FP&A and Investor RelationsTravis Steed - Managing DirectorConference Call ParticipantsNone - AnalystNone - AnalystOperatorGood afternoon, and welcome to SI-BONE's Fourth Quarter 2025 Earnings Co ...

SI-BONE (NasdaqGM:SIBN) Q4 2025 Earnings call February 23, 2026 04:30 PM ET Speaker5Good afternoon, and welcome to SI-BONE's fourth quarter 2025 earnings conference call. At this time, all participants are in listen-only mode. We will be facilitating a question and answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Saqib Iqbal, Vice President, FP&A, and Investor Relations at SI-BONE, for a few introductory ...

Trauma and Extremities partnership aligns disciplined approach to portfolio optimization and focuses on delivering long-term value for surgeons and patients Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announced it has signed a distribution agreement with SI-BONE, focused on their innovative iFuse TORQ portfolio. This collaboration expands the Smith+Nephew portfolio offerings for percutaneous pelvic fracture fixation procedures and strengthens our position in high-frequency ...

Achieves 20% worldwide revenue growth and positive adjusted EBITDA for Fiscal Year 2025Generates free cash flow in the Fourth Quarter 2025 SANTA CLARA, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights (all comparisons are to the prior ...

Core Insights - Smith+Nephew announces findings from a comparative study on single-use negative pressure wound therapy (sNPWT) devices, highlighting the benefits of PICO sNPWT in reducing surgical complications and healthcare costs [1][2]. Study Findings - The study analyzed data from over 22,000 patients, showing that prophylactic use of PICO sNPWT (-80 mmHg) significantly reduces the risk of wound dehiscence, hospital length of stay (LoS), and overall healthcare costs compared to PrevenaTM (-125 mmHg) sNPWT [2][3]. - Key findings include a 57.8% relative reduction in wound dehiscence risk, a 9.1% relative reduction in LoS (6.33 days vs. 6.86 days), and a 10.34% relative reduction in admission-related costs [5]. Economic Impact - The use of PICO sNPWT resulted in substantial cost savings, with a 21.95% relative reduction in mean index admission cost and a 21% reduction in costs at 30- and 90-day post-surgery [5][6]. - The study indicates that PICO sNPWT may help reduce surgical site complications (SSCs) for at-risk patients, thereby alleviating strain on healthcare resources [6]. Clinical Recommendations - The findings align with global recommendations from organizations such as NICE, WHO, and ACS/SIS, which advocate for the use of incisional negative pressure wound therapy (iNPWT) to minimize the risk of surgical site infections (SSIs) [6][14].

Core Insights - Smith+Nephew announces findings from a comparative study of single-use negative pressure wound therapy (sNPWT) devices, highlighting the benefits of PICO sNPWT in reducing surgical site complications [1][2] Study Findings - The study analyzed data from over 22,000 patients, showing that prophylactic use of PICO sNPWT (-80 mmHg) significantly reduces the risk of wound dehiscence, hospital length of stay (LoS), and overall healthcare costs compared to Prevena sNPWT (-125 mmHg) [2][4] - Key findings include a 57.8% relative reduction in wound dehiscence risk, a 9.1% relative reduction in LoS (6.33 days vs. 6.86 days), and a 10.34% relative reduction in admission-related costs [6] Economic Impact - The use of PICO sNPWT is associated with substantial cost savings, particularly for patients with comorbidities such as obesity, diabetes, and hypertension, contributing to reduced surgical site complications and improved health economic outcomes [5][6] Clinical Recommendations - The findings support the growing evidence for the prophylactic use of incisional negative pressure wound therapy (iNPWT) across various surgeries, aligning with global recommendations from NICE, WHO, and ACS/SIS guidelines [7]

Core Insights - Smith+Nephew has launched CORIOGRAPH Pre-Op Planning and Modeling Services for total shoulder arthroplasty in the United States, enhancing its CORIOGRAPH Services portfolio which already includes solutions for knee and hip arthroplasty [1][5] - The new software provides image-based planning capabilities, allowing surgeons to create patient-specific plans for shoulder replacement procedures through advanced biomechanical simulation [1][6] - The AETOS Shoulder System is designed to work seamlessly with CORIOGRAPH Services, improving surgical efficiency and decision-making in the operating room [4][8] Product Features - CORIOGRAPH Services support 3D CT-based planning, enabling visualization of implant options and optimization of component positioning with patient-specific anatomical modeling [6] - The system minimizes impingement through personalized service and tools for surgeon planning, enhancing the overall surgical experience [6] - Unique features include range-of-motion and impingement simulation, which help optimize implant placement based on patient-specific shoulder kinematics [6] Strategic Vision - The addition of shoulder pre-op planning to the CORIOGRAPH Services platform aligns with Smith+Nephew's vision of personalized orthopedic care across hip, knee, and shoulder replacements [5] - The company emphasizes investment in data-driven and patient-centric tools to empower surgeons in delivering tailored care for each patient [5]